Research Alliance II (Research Alliance II) ROCE % : -0.46% (As of Sep. 2022)

View and export this data going back to 2021. Start your Free Trial

What is Research Alliance II ROCE %?

ROCE % measures how well a company generates profits from its capital. It is calculated as EBIT divided by Capital Employed, where Capital Employed is calculated as Total Assets minus Total Current Liabilities. Research Alliance II's annualized ROCE % for the quarter that ended in Sep. 2022 was -0.46%.

Research Alliance II ROCE % Historical Data

The historical data trend for Research Alliance II's ROCE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Research Alliance II ROCE % Chart

Research Alliance II Annual Data

Trend

Dec20

Dec21

ROCE %

-0.62

Research Alliance II Quarterly Data
	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22
ROCE %	Get a 7-Day Free Trial			-0.39	-0.41	-0.81	-0.46	-0.46

Research Alliance II ROCE % Calculation

Research Alliance II's annualized ROCE % for the fiscal year that ended in Dec. 2021 is calculated as:

ROCE %	=	EBIT	/	( (Capital Employed	+	Capital Employed)	/ count )
		(A: Dec. 2021 )		(A: Dec. 2020 )		(A: Dec. 2021 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(A: Dec. 2021 )		(A: Dec. 2020 )		(A: Dec. 2021 )
	=	-0.468	/	( ( (0.348 - 0.33)	+	(150.767 - 0.178) )	/ 2 )
	=	-0.468	/	( (0.018	+	150.589)	/ 2 )
	=	-0.468	/	75.3035
	=	-0.62 %

Research Alliance II's ROCE % of for the quarter that ended in Sep. 2022 is calculated as:

ROCE %	=	EBIT ⁽¹⁾	/	( (Capital Employed	+	Capital Employed)	/ count )
		(Q: Sep. 2022 )		(Q: Jun. 2022 )		(Q: Sep. 2022 )
	=	EBIT	/	( ( (Total Assets - Total Current Liabilities)	+	(Total Assets - Total Current Liabilities) )	/ count )
		(Q: Sep. 2022 )		(Q: Jun. 2022 )		(Q: Sep. 2022 )
	=	-0.692	/	( ( (150.484 - 0.168)	+	(150.87 - 0.068) )	/ 2 )
	=	-0.692	/	( ( 150.316	+	150.802 )	/ 2 )
	=	-0.692	/	150.559
	=	-0.46 %

(1) Note: The EBIT data used here is four times the quarterly (Sep. 2022) EBIT data.

Research Alliance II (NAS:RACB) ROCE % Explanation

ROCE % can be especially useful when comparing the performance of capital-intensive companies. Unlike ROE %, which indicates the profitability of Shareholders Equity, ROCE % also considers long-term debt in Capital Employed. This can be helpful when analyzing companies with significant debt, as the result is neutralized by taking debt into consideration.

Generally speaking, a higher ROCE % indicates a stonger profitability for a company. Moreover, it is important to look at the ratio from a long term perspective. Investors tend to favor companies with stable and rising ROCE % trend over those with volatile ones.

Research Alliance II ROCE % Related Terms

Thank you for viewing the detailed overview of Research Alliance II's ROCE % provided by GuruFocus.com. Please click on the following links to see related term pages.

Research Alliance II (Research Alliance II) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Financial Services » Diversified Financial Services » Research Alliance Corp II (NAS:RACB) » Definitions » ROCE %

Comparable Companies

Traded in Other Exchanges

N/A

Address

3172 North Rainbow Boulevard, Suite 1278, Las Vegas, NV, USA, 89108

Website

https://www.researchalliancecorp.com

Research Alliance Corp II is a blank check company.

Executives

Saba Capital Management, L.p.	10 percent owner	405 LEXINGTON AVENUE, 58TH FLOOR, NEW YORK NY 10174
Boaz Weinstein	10 percent owner	405 LEXINGTON AVENUE, 58TH FLOOR, NEW YORK NY 10174
Peter Kolchinsky	director, officer: Chief Executive Officer	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Stephen J Hoffman	director	C/O SKYLINE VENTURES, 525 UNIVERSITY AVE., SUITE 1350, PALO ALTO CA 94301
Thomas Leggett	director	C/O AXCELLA HEALTH INC., 840 MEMORIAL DRIVE, CAMBRIDGE MA 02139
Matthew Hammond	director, officer: Chief Investment Officer	200 BERKELEY STREET, 18TH FLOOR, BOSTON MA 02116
Research Alliance Holdings Ii Llc	10 percent owner	200 BERKELEY STREET 18TH FLOOR, BOSTON MA 02116
Theresa Cameron	director, 10 percent owner, officer: Chief Financial Officer	C/O THERAPEUTICS ACQUISITION CORP., 200 BERKELEY STREET. 18TH F L, BOSTON MA 02116
Clive Patience	director	C/O RESEARCH ALLIANCE CORP. II, 3172 NORTH RAINBOW BLVD. SUITE 1278, LAS VEGAS NV 89108

Research Alliance II (Research Alliance II) Headlines

From GuruFocus

Research Alliance Corp. II Will Redeem Public Shares

By Business Wire Business Wire • 11-28-2022

POINT Biopharma Receives U.S. Nuclear Regulatory Commission Materials License for Indiana Facility

By Business Wire Business Wire • 04-28-2021